



## PRESS RELEASE

---

### ASLAN PHARMACEUTICALS ANNOUNCES PRESENTATION OF NEW PRE-CLINICAL DATA ON VARLITINIB IN HEPATOCELLULAR CARCINOMA AT AACR

Singapore, 17 April, 2018 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced the presentation of new data from a study of the use of *varlitinib* in hepatocellular carcinoma (HCC) at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois.

#### Details of the poster are as below:

**Session:** Experimental and Molecular Therapeutics  
**Poster #:** 3992 / 26  
**Section:** 41  
**Title:** Varlitinib demonstrates tumor regression and vessel normalization in ErbB-dependent and mutated beta-catenin hepatocellular carcinoma patient-derived xenograft model

The pre-clinical study was conducted in collaboration with the National Cancer Centre Singapore (NCCS) and was led by Professor The Huynh Hung, Principal Investigator at NCCS' Laboratory of Molecular Endocrinology. The study was designed to demonstrate the efficacy of *varlitinib* in HCC patient-derived xenograft (PDX) models and to study the molecular mechanisms of *varlitinib*-mediated tumor suppression and its anti-angiogenic potential. In addition, the study sought to identify gene signatures associated with efficacy of *varlitinib* by transcriptome and gene expression analyses.

Ends

#### Media and IR contacts

**Chris Fang**

ASLAN Pharmaceuticals

Tel: +886 2 2758 3333

Email: [media@aslanpharma.com](mailto:media@aslanpharma.com)

**Emma Thompson / Stephanie Tan**

Spurwing Communications

Tel: +65 6340 7287

Email: [ASLAN@spurwingcomms.com](mailto:ASLAN@spurwingcomms.com)

**Robert H Uhl**

Westwicke Partners

Tel: +1 858 356 5932

Email: [robert.uhl@westwicke.com](mailto:robert.uhl@westwicke.com)

#### About *varlitinib* (ASLAN001)

*Varlitinib* (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, *varlitinib* could inhibit proliferation and control tumor growth. *Varlitinib* is currently being studied in gastric, biliary tract, breast and colorectal cancers. *Varlitinib* has been granted orphan drug designation in the United States for gastric cancer and cholangiocarcinoma, a sub-type of biliary tract cancer, and was awarded orphan drug designation for the treatment of biliary tract cancer by the Ministry of Food and Drug Safety in South Korea.

#### About ASLAN Pharmaceuticals

ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company



developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN's portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN's partners include Array BioPharma, Bristol-Myers Squibb, Ammirall and CSL. For additional information please visit [www.aslanpharma.com](http://www.aslanpharma.com).